SEARCH

SEARCH BY CITATION

References

  • 1
    Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010; 31: 93849.
  • 2
    Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599608.
  • 3
    Wald A, Scarpignato C, Kamm MA et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007; 26: 22736.
  • 4
    Tack J, Mueller-Lissner S, Dubois D, Schenck F. Only 27% of European patients with chronic constipation are satisfied with current treatment options. UEGW/WCOG: Gut 2009; 58 (Suppl. II): A181.
  • 5
    Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 31307.
    Direct Link:
  • 6
    Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999; 94: 353040.
    Direct Link:
  • 7
    Wald A, Scarpignato C, Mueller-Lissner S et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008; 28: 91730.
  • 8
    Eoff JC. Optimal treatment of chronic constipation in managed care: review and roundtable discussion. J Manag Care Pharm 2008; 14: 115.
  • 9
    Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol 1999; 94: 60915.
    Direct Link:
  • 10
    Rao SSC. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003; 32: 65983.
  • 11
    Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996; 91: 2632.
  • 12
    Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol 1999; 94: 60915.
    Direct Link:
  • 13
    Bassotti G, Imbimbo BP, Betti C, Dozzini G, Morelli A. Impaired colonic motor response to eating in patients with slow-transit constipation. Am J Gastroenterol 1992; 87: 5048.
  • 14
    Bassotti G, Gaburri M, Imbimbo BP et al. Colonic mass movements in idiopathic chronic constipation. Gut 1988; 29: 11739.
  • 15
    Emmanuel AV, Kamm MA. Response to a behavioral treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomic innervation. Gut 2001; 49: 2149.
  • 16
    Bazzocchi G, Ellis J, Villanueva-Meyer J et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990; 98: 68693.
  • 17
    Krishnamurthy S, Schuffler MD, Rohrmann CA, Pope CE, 2nd. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 1985; 88: 2634.
  • 18
    He CL, Burgart L, Wang L et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology 2000; 118: 1421.
  • 19
    Bassotti G, Chiarioni G, Imbimbo BP et al. Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation. Dig Dis Sci 1993; 38: 10405.
  • 20
    Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 3443.
  • 21
    Costedio MM, Coates MD, Brooks EM et al. Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation. Am J Gastroenterol 2010; 105: 117380.
  • 22
    Knowles CH, Scott SM, Lunniss PJ. Slow transit constipation: a disorder of pelvic autonomic nerves? Dig Dis Sci 2001; 46: 389401.
  • 23
    Kamm MA, Farthing MJG, Lennard-Jones JE, Perry L, Chard T. Steroid hormone abnormalities in women with severe idiopathic constipation. Gut 1991; 32: 804.
  • 24
    Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 2005; 128: 66775.
  • 25
    Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 1998; 93: 104250.
    Direct Link:
  • 26
    Rao SSC. Dyssynergic defecation. Gastroenterol Clin North Am 2001; 31: 97114.
  • 27
    Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130: 65764.
  • 28
    Rao SS, Seaton K, Miller M et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007; 5: 3318.
  • 29
    Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007; 50: 42841.
  • 30
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 31
    Locke G III, Pemberton J, Phillips S. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology 2000; 119: 17616.
  • 32
    American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005; 100: S14.
    Direct Link:
  • 33
    Kellow JE. Introduction: a practical evidence-based approach to the diagnosis of the functional gastrointestinal disorders. Am J Gastroenterol 2010; 105: 7436.
  • 34
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastoenterol 1997; 32: 9204.
  • 35
    Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol 2010; 105: 77585.
  • 36
    Bharucha AE, Wald AM. Anorectal disorders. Am J Gastroenterol 2010; 105: 78694.
  • 37
    Muller-Lissner S. The pathophysiology, diagnosis and treatment of constipation. Dtsch Arztebl Int 2009; 106: 42431.
  • 38
    Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am J Gastroenterol 2008; 103: 8202.
    Direct Link:
  • 39
    Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003; 32: 65983.
  • 40
    Ternent CA, Bastawrous AL, Morin NA, Ellis CN, Hyman NH, Buie WD. Practice parameters for the evaluation and management of constipation. Dis Colon Rectum 2007; 50: 201322.
  • 41
    Johnson D. Treating chronic constipation: how should we interpret the recommendations? Clin Drug Investig 2006; 26: 54757.
  • 42
    Tack J, Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009; 7: 5028.
  • 43
    Jones M, Talley N, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002; 47: 222230.
  • 44
    Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, Muller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997; 92: 958.
  • 45
    Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001; 10: 26873.
  • 46
    Dupont C, Leluyer B, Maamri N et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005; 41: 62533.
  • 47
    Di Palma JS, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol 2007; 102: 196471.
    Direct Link:
  • 48
    Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007; 102: 143641.
    Direct Link:
  • 49
    Migeon-Duballet I, Chabin M, Gautier A et al. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin 2006; 22: 122735.
  • 50
    Corazziari E, Badiali D, Bazzocchi G et al. Long term efficacy, safety and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000; 46: 5226.
  • 51
    Loening-Baucke V, Pashankar D. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics 2006; 118: 52835.
  • 52
    Bosshard W, Dreher R, Schnegg J, Bula C. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004; 21: 91130.
  • 53
    Mueller-Lissner S, Kamm MA, Wald A et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010; 105: 897903.
  • 54
    Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 93671.
    Direct Link:
  • 55
    Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005; 100: S522.
    Direct Link:
  • 56
    Bengtsson M, Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate. Gastroenterol Nurs 2005; 28: 312.
  • 57
    Morales MA, Hernandez D, Bustamante S, Bachiller I, Rojas A. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity? J Toxicol 2009; 2009: 287247.
  • 58
    Ramkumar DP, Rao SSC. Functional anorectal disorders. In: IrvineEJ, HuntRH, eds. Evidence-Based Gastroenterology. London: B C Decker, 2001: 20722.
  • 59
    Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol 2008; 43: 336.
  • 60
    Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C117383.
  • 61
    Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging 2008; 3: 35764.
  • 62
    Wood JD. Enteric nervous system: sensory physiology, diarrhea and constipation. Curr Opin Gastroenterol 2010; 26: 1028.
  • 63
    Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010; 55: 10907.
  • 64
    Sucampo Pharma Europe Ltd. Sucampo receives marketing authorization for Amitiza® in Switzerland for treatment of chronic idiopathic constipation, 2009. Available at: http://www.sucampo.com (accessed on 7 June 2010).
  • 65
    Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006; 24: 5969.
  • 66
    Tonini M, de Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13: 158591.
  • 67
    Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H25348.
  • 68
    de Maeyer J, Lefebvre R, Schuurkes J. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20: 99112.
  • 69
    Busti AJ, Murillo JR Jr, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 52631.
  • 70
    Chan KY, de Vries R, Leijten FP et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol 2009; 619: 617.
  • 71
    Briejer MR, Bosmans JP, Van Daele P et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001; 423: 7183.
  • 72
    Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 6826.
  • 73
    Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 35460.
  • 74
    Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 234454.
  • 75
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 31528.
  • 76
    Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 35765.
  • 77
    Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the patient assessment of constipation – quality of life (PAC-QOL) questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2009; 22: e5463.
  • 78
    Tack J, Ausma J, Kerstens R, Vanderplassche L. Safety and tolerability of prucalopride (Resolar) in patients with chronic constipation: pooled data from three pivotal phase III studies. Gastroenterology 2008; 134: A530.
  • 79
    Boyce M, Kerstens R, Beyens G, Ausma J, Vandeplassche L. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials. Gastroenterology 2009; 136(Suppl. 1): T1265.
  • 80
    Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009; 21: 1256e117.
  • 81
    Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010; 32: 111323.
  • 82
    Mueller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010; 22: 9918.
  • 83
    Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic non-cancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010; 55: 291221.
  • 84
    Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010; 23: 61622.
  • 85
    Meissner W, Leyendecker P, Mueller-Lissner S et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 5664.
  • 86
    Tan EK, Cornish J, Darzi AW, Tekkis PP. Meta-analysis: alvimopan vs placebo in the treatment of postoperative ileus. Aliment Pharmacol Ther 2007; 25: 4757.
  • 87
    Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004; 16(Suppl. 2): 4653.
  • 88
    Kelleher D, Johanson J, Pobiner B, Carter E, Dukes G. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist- a study in patients with chronic idiopathic constipation (CIC) not taking opioid medications. Am J Gastroenterol 2006; 101: S480 [Abstract 1239].
  • 89
    Johnston JM, Kurtz CB, Drossman DA et al. Pilot study on the effects of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009; 104: 12532.
  • 90
    Lembo AJ, Schneier H, Lavins BJ et al. Efficacy and safety of once daily linaclotide administered orally for 12 weeks in patients with chronic constipation: results from two randomized, double-blind, placebo-controlled phase 3 trials. Presented at DDW, May 1–5 2010. Abstract [286].
  • 91
    Lembo AJ, Kurtz CB, Macdougall JE et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138: 88695 e1.
  • 92
    Carson RT, Tourkodimitris S, Macdougall JE et al. Effect of linaclotide on quality of life in adults with chronic constipation: results from two randomized, double-blind, placebo-controlled phase 3 trials. Presented at DDW, May 1–5 2010. Abstract [847d].
  • 93
    Johnston JM, Schneier H, Lavins BJ et al. Results from the randomized withdrawal period of a phase 3 clinical trial of linaclotide in chronic constipation. Presented at DDW, May 1–5 2010. Abstract [T1817].
  • 94
    Michael RG, Yu-Ping L, Kenneth P, John FJ, Allen WM, Michael MK. T1389 TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008; 134: A545.
  • 95
    Camilleri M, Vazquez-Roque M, Burton D et al. Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007; 19: 308.
  • 96
    World Gastroenterology Organisation. WGO-OMGE Practice Guideline: constipation. 2007. Available at:http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/05_constipation.pdf (accessed on 24 August 2010).
  • 97
    Piche T, Dapoigny M, Bouteloup C et al. Recommandations pour la pratique clinique dans la prise en charge et le traitement de la constipation chronique de l’adulte. Gastroentérol Clin Biol 2007; 31: 12535.
  • 98
    NICE. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care (CG61). 2008.